object
human
bocaviru
hbov
frequent
identifi
children
respiratori
tract
infect
role
acut
otiti
media
aom
suggest
diseas
associ
close
relat
bocavirus
remain
unknown
increas
evid
show
probiot
may
reduc
risk
aom
viral
origin
object
studi
examin
preval
persist
bocavirus
consecut
nasopharyng
sampl
np
otitispron
children
whether
associ
exist
hbov
child
characterist
respiratori
symptom
aom
pathogen
whether
probiot
reduc
occurr
hbov
method
doubleblind
placebocontrol
random
intervent
studi
otitispron
children
age
month
year
consum
daili
either
one
capsul
probiot
lactobacillu
rhamnosu
gg
l
rhamnosu
bifidobacterium
breve
propionibacterium
freudenreichii
js
placebo
clinic
examin
np
collect
threetim
point
presenc
persist
dna
np
determin
rtqpcr
baselin
month
result
high
load
copiesml
hbov
dna
detect
children
show
prolong
presenc
hbov
least
month
none
dna
higher
number
sibl
associ
increas
hbov
preval
p
preval
persist
hbov
significantli
associ
characterist
respiratori
symptom
aom
pathogen
probiot
intervent
significantli
reduc
number
hbov
dnaposit
sampl
probiot
vs
placebo
vs
ci
p
conclus
hbov
dna
occur
often
nasopharynx
otitispron
children
may
persist
month
probiot
treatment
possibl
reduc
presenc
hbov
elsevi
ireland
ltd
right
reserv
promot
colon
aom
pathogen
probiot
bacteria
offer
attract
option
reestablish
microbi
equilibrium
prevent
infecti
diseas
lactobacillu
rhamnosu
gg
particular
effect
prevent
upper
respiratori
tract
infect
reduc
risk
acut
rti
children
attend
daycar
otitispron
children
probiot
combin
l
rhamnosu
gg
l
rhamnosu
bifidobacterium
breve
propionibacterium
freudenreichii
js
ineffect
reduc
aom
recurr
nasal
colon
bacteri
pathogen
probiot
treatment
howev
decreas
recurr
upper
respiratori
tract
infect
urti
suggest
probiot
effect
viral
respiratori
infect
primari
object
studi
examin
qpcr
preval
prolong
presenc
persist
nasopharynx
otitispron
children
learn
whether
probiot
combin
might
reduc
hbov
prevalencepersist
cold
season
addit
look
associ
hbov
child
characterist
respiratori
symptom
aom
pathogen
studi
protocol
approv
ethic
committe
helsinki
univers
central
hospit
written
inform
consent
parent
guardian
children
recruit
newspap
advertis
primari
health
care
centr
daycar
centr
internet
children
classifi
otitispron
aom
episod
preced
month
episod
preced
month
children
undergon
adenoidectomi
tympanostomi
accept
suffer
requir
number
aom
episod
research
conduct
conjunct
substudi
studi
popul
part
larger
project
describ
hatakka
et
al
briefli
doubleblind
placebocontrol
random
intervent
studi
septemb
april
origin
otitispron
children
month
year
old
consum
daili
either
one
capsul
probiot
l
rhamnosu
gg
l
rhamnosu
b
breve
p
freudenreichii
js
n
placebo
n
np
sampl
collect
describ
schedul
baselin
visit
autumn
first
followup
visit
month
winter
final
visit
month
spring
present
studi
three
np
sampl
avail
otitispron
children
placebo
probiot
group
parent
receiv
advic
avoid
day
child
respiratori
symptom
make
schedul
collect
visit
parent
keep
daili
diari
includ
sign
symptom
aom
respiratori
infect
fever
earach
otorrhoea
rhiniti
cough
sore
throat
chest
wheez
night
restless
list
visit
health
care
author
use
medic
np
baselin
visit
visit
analyz
pcr
follow
hybrid
rhinovirus
enterovirus
baselin
visit
visit
inocul
sheep
bloodor
chocolateagar
plate
streptococcu
pneumonia
haemophilu
influenza
moraxella
catarrhali
describ
dna
purifi
ml
sampl
qiaamp
dna
mini
kit
qiagen
gmbh
hilden
germani
accord
manufactur
instruct
initi
realtim
quantit
pcr
specif
hbov
gene
perform
describ
multiplex
reaction
detect
execut
accord
kantola
et
al
criteria
posit
reaction
cycl
threshold
cycl
fluoresc
count
minimum
genom
viral
load
allow
reproduc
quantif
copi
per
reaction
correspond
copiesml
origin
np
specimen
hbov
assess
posit
neg
four
posit
criteria
copiesml
sampl
cochran
qtest
adjust
pairwis
comparison
serv
analyz
chang
hbov
dnaposit
schedul
visit
chisquar
test
serv
analyz
associ
categor
baselin
characterist
children
hbov
preval
persist
analyz
associ
hbov
dnaposit
respiratori
symptom
sampl
day
ae
week
sampl
day
ae
week
timeperiod
logist
regress
analysi
gee
gener
estim
equat
use
inform
respiratori
symptom
provid
parent
presenc
respiratori
symptom
hbov
dnaposit
children
compar
hbov
dnaneg
children
result
odd
ratio
confid
interv
addit
logist
regress
gee
analys
allow
studi
associ
aom
pathogen
hbov
dnaposit
logist
regress
analysi
allow
studi
possibl
effect
probiot
intervent
hbov
result
unadjust
crude
baselineadjust
odd
ratio
confid
interv
gee
analysi
allow
inclus
visit
simultan
baselin
posit
categor
covari
pvalu
consid
statist
signific
data
analyz
spss
version
spss
inc
chicago
il
usa
otitispron
children
children
age
month
year
mean
year
examin
nasopharyng
carriag
cold
period
septemb
april
exhibit
high
load
copiesml
sampl
hbov
dna
tabl
dna
undetect
studi
children
hbov
dna
detect
three
visit
highest
occurr
month
fig
initi
visit
children
carri
high
load
hbov
dna
month
hbov
dna
preval
among
np
sampl
increas
month
decreas
chang
hbov
dna
preval
statist
signific
cochran
q
test
tabl
number
children
first
occurr
hbov
dna
np
among
otitispron
children
viral
load
rang
copiesml
sampl
studi
period
p
due
increas
baselin
month
post
hoc
test
p
hbovdna
load
rang
copiesml
np
sampl
fig
children
show
prolong
presenc
hbov
dna
least
month
one
child
month
addit
children
one
neg
sampl
two
hbov
dnaposit
sampl
children
persist
hbov
dna
viral
load
remain
copiesml
sampl
wherea
viral
load
initi
copiesml
viral
load
increas
hbov
preval
significantli
higher
among
children
sibl
among
sibl
vs
p
moreov
children
care
home
show
less
persist
hbov
dna
p
tabl
risk
factor
aom
includ
age
gender
parent
smoke
use
pacifi
aom
episod
studi
associ
hbov
preval
persist
number
day
respiratori
symptom
distribut
baselin
characterist
children
hbov
preval
persist
nasopharynx
three
posit
criteria
group
baselin
characterist
hbov
regard
posit
first
occurr
baselin
month
month
visit
requir
persist
least
two
consecut
posit
copiesml
sampl
chisquar
test
use
test
associ
baselin
characterist
hbov
posit
pvalu
consid
signific
children
pneumonia
h
influenza
catarrhali
detect
baselin
visit
rhinoviru
enteroviru
detect
studi
visit
baselin
visit
codetect
rate
hbov
dnaposit
sampl
rhinoviru
enteroviru
visit
codetect
rate
visit
codetect
rate
respect
associ
appear
presenc
hbov
dna
aom
pathogen
tabl
children
experienc
respiratori
symptom
fever
earach
cough
rhiniti
sore
throat
chest
wheez
discharg
ear
followup
median
iqr
number
day
respiratori
symptom
associ
appear
hbov
dnaposit
sampl
copi
ml
respiratori
symptom
either
week
sampl
collect
addit
hbov
dna
posit
although
analyz
placebo
group
show
associ
individu
respiratori
symptom
cough
wheez
probiot
supplement
reduc
significantli
number
hbov
dnaposit
sampl
copiesml
intervent
period
probiot
vs
placebo
vs
baselin
adjust
ci
p
similar
though
statist
signific
reduct
occur
result
analyz
gee
baselin
adjust
ci
p
appli
anoth
hbovposit
criterion
tabl
addit
allow
time
intervent
take
place
includ
baselin
hbovneg
children
analyz
hbovposit
children
first
occurr
hbov
found
less
hbov
probiot
group
probiot
vs
placebo
vs
ci
p
probiot
intervent
howev
reduc
occurr
prolong
presenc
hbov
month
vs
ci
p
human
bocaviru
commonli
present
nasopharynx
otitispron
children
cold
period
even
free
respiratori
symptom
altogeth
hbov
dna
detect
children
sampl
viral
load
copiesml
origin
sampl
dna
np
sampl
detect
howev
rare
occur
respiratori
secret
identifi
stool
sampl
hbov
typic
occur
respiratori
sampl
children
age
hospit
lower
respiratori
tract
diseas
wherea
adult
hbov
rare
howev
recent
studi
report
hbov
dna
upper
airway
also
asymptomat
children
children
visit
schedul
sampl
asymptomat
hbov
dna
detect
np
show
high
viral
load
find
could
explain
fact
tabl
number
hbov
dnaposit
children
base
differ
posit
criteria
studi
group
requir
persist
least
two
consecut
posit
copiesml
sampl
observ
prolong
presenc
hbov
dna
least
month
children
high
viral
load
one
child
hbov
dna
persist
throughout
entir
studi
period
otitispron
children
increas
mucu
abnorm
nasopharyng
structur
may
favor
hbov
persist
addit
identifi
two
children
hbovposit
np
sampl
taken
month
apart
neg
sampl
find
could
attribut
mucos
contamin
differ
mucu
secret
fluctuat
viru
shed
reinfect
also
like
hbov
occur
nasopharynx
asymptomat
visit
may
influenc
detect
persist
quantit
pcr
detect
hbov
offer
insight
clinic
impact
hbov
hbov
high
viral
load
copiesml
associ
rti
cutoff
howev
hbov
appear
often
innoc
bystand
remnant
past
infect
thu
hbov
pcr
posit
nasopharynx
alon
insuffici
implic
hbov
pathogenesi
acut
rti
hbov
pcr
posit
np
criterion
diagnosi
case
acut
hbov
infect
evidenc
viremia
serodiagnosi
would
miss
moreov
fals
diagnos
may
ensu
perhap
result
persist
hbov
dna
primari
infect
mucos
contamin
serolog
test
coupl
qpcr
could
aid
studi
trustworthi
causal
associ
hbov
respiratori
diseas
line
confirm
presenc
hbov
dna
np
even
high
viral
load
associ
significantli
respiratori
symptom
report
week
schedul
samplecollect
period
children
visit
centr
sampl
healthi
major
respiratori
symptom
thu
expect
sampl
time
regard
associ
baselin
characterist
preval
hbov
children
month
number
sibl
type
daycar
may
associ
hbov
preval
persist
higher
number
sibl
correl
high
hbov
preval
perhap
suscept
hbov
infect
mucos
contamin
may
fall
fewer
sibl
spread
viru
viral
infect
nasopharynx
may
prime
superinfect
bacteri
pathogen
unknown
mechan
instanc
pneumonia
play
major
role
develop
pneumonia
associ
influenza
parainfluenza
respiratori
syncyti
virus
hbov
dna
nasopharynx
associ
presenc
bacteri
pathogen
pneumonia
h
influenza
catarrhali
rhinoor
enterovirus
interestingli
children
aom
beder
et
al
found
posit
correl
hbov
pneumonia
middleear
fluid
mef
mef
sampl
avail
confirm
antibiot
common
treatment
aom
although
aom
usual
selflimit
respiratori
virus
also
involv
clinic
cours
recurr
use
antibiot
lead
antibiot
resist
disturb
microflora
balanc
facilit
colon
aom
pathogen
probiot
could
serv
altern
therapi
prevent
infecti
diseas
balanc
microbi
equilibrium
enhanc
mucos
immun
compet
bacteri
adhes
site
otitispron
children
combin
probiot
l
rhamnosu
gg
l
rhamnosu
b
breve
p
freudenreichii
js
fail
reduc
aom
recurr
nasal
colon
bacteri
pathogen
nevertheless
probiot
treatment
reduc
recurr
urti
may
impli
probiot
effect
respiratori
infect
viral
etiolog
particular
probiot
strain
l
rhamnosu
gg
effect
prevent
children
upper
respiratori
tract
infect
interestingli
found
probiot
treatment
reduc
significantli
number
hbov
dnaposit
sampl
p
month
intervent
margin
also
amount
hbovposit
children
howev
number
children
studi
group
unequ
studi
necessari
order
confirm
observ
conclus
hbov
commonli
occur
upper
airway
otitispron
children
although
nasopharynx
show
correl
respiratori
symptom
addit
prolong
recurr
hbov
dna
may
observ
month
probiot
treatment
possibl
effect
hbov
studi
support
grant
ivikki
sakari
sohlberg
foundat
special
government
subsidi
health
scienc
research
finland
foundat
nutrit
research
financi
contribut
liisa
lehtoranta
doctor
studi
katja
hatakka
employe
valio
ltd
author
disclos
conflict
interest
